Other

Apceth Gmbh & Co Kg

Junctucell Biomed Manufacturing Gmbh

Nelson, Peter Jon

Ralf Huss

Peter Nelson

Christine Günther

Manfred J Stangl

Matthias C Raggi

Stefanos Theoharis

Felix Hermann

Matthias Raggi

Peter Jon Nelson

Günther Eissner

Daria Larissa Forster

Gunther Eissner

Christine Guenther

Manfred Stangl

Sabine Geiger-schredelseker

A method of treating a tumor in a subject including administering a genetically modified mesenchymal stem cell (MSC), wherein the MSC includes one or more exogenous nucleic acid molecule(s), wherein the one or more exogenous nucleic acid molecule(s) includes one or more regions encoding two or more immune response-stimulating cytokines operably linked to one or more promoters or promoter/enhancer combinations, wherein the two or more immune response-stimulating cytokines include at least IL-7, and at least one of IL-12 or IL-21.

Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells

The present invention relates to fusion constructs of glycosylphosphatidylinositol (GPI)-anchored tissue inhibitors of metalloproteinases (TIMPs) and their use for the treatment of cancer and in regenerative medicine. By this approach, the GPI-anchored TIMP proteins are incorporated into the surface membrane of tumor cells and render tumor cells sensitive to FAS-induced apoptosis. Furthermore, the fusion constructs of the present invention are effective agents useful in wound healing applications. In one embodiment, the TIMP is linked to mucin followed by GPI in order to enhance surface presentation. The use of GPI to link TIMP renders the resulting fusion protein particularly useful as an anti-cancer agent for the treatment of cancer, and, in particular, any residual cancer following an incomplete surgical resection of primary tumors in an individual.

Tissue inhibitor of metalloproteinases (TIMP) linked to glycosylphosphatidylinositol (GPI)-anchors for treatment of cancer and skin lesions

This invention provides novel stem cell-based methods for treating a number of conditions. These methods employ CD34stem cells, and have a tremendous advantage in that they do not require myeloablation in the subject being treated. The CD34stem cells used in the instant methods can be genetically modified or not, depending on the disorder treated.

CD34 stem cell-related methods and compositions

The invention relates to the use of genetically modified, very early haematopoietic and mesenchymal stem cells (negative for the expression of the surface molecule CD34) in the individual gene therapy of mono- or oligogenetic diseases or in cell therapy. Autologous CD34-negative adherently growing stem cell cultures from the peripheral blood of the patient are applied and efficiently tranfected or infected with genetic constructs. The gene products of these genes should substitute defective or absent proteins or factors in the patient organism in the long term. After expansion, the autologous stem cells can also be used for cell therapy (organ replacement therapy).

Genetically modified CD34-negative adherently growing stem cells and their use in gene therapy

Growing community of inventors

Waakirchen, Germany

Ralf Huss